PACE Talks

The role of HDL in atherosclerosis

News - Dec. 21, 2011

Prof. John Chapman (Paris, France) and dr. Kees Hovingh (Amsterdam, The Netherlands) discuss about the role of HDL in atherosclerosis.
'I think studying families with carries of mutations in those pivotal genes is only one model', Hovingh tells about the relationship between functional mutations in the major genes involved in HDL metabolism and cardiovascular risk. For example, mutations in LCAT, ABCA1, and ApoA-1 studied in terms of surrogate markers. In his view, ApoA-1 is one of the best targets of atherosclerosis.
'I think we are at a watershed in this field', Chapman adds. 'We really need in the international community to move together to try to define the most informative experimental systems that we should be using for the future.'

Topics discussed in this PACE talk:

  • Relationship between mutations in HDL metabolism and cardiovascular risk
  • Better view of the landscape of genetic disorders underpinning HDL levels
  • Systems biology: relationship between in vitro and in vivo studies
  • Complexity of the HDL or ApoA-1 ligand
  • Controversy: association with the systems that have been used

View the slides

The role of HDL in atherosclerosis
Genetics (1)
Genetics of HDL metabolism (1)
HDL metabolism
Genetics of HDL metabolism (2)
Genetics (2)
Genetics of HDL metabolism (2)
Systems biology
Systems biology (1)
Systems biology (2)
HDL-mediated cholesterol efflux from cholesterol-rich macrophages
Systems biology (3)
Mechanisms of cellular cholesterol efflux to HDL particles
HDL metabolism: impact of CETP inhibition
Systems biology (4)

Facebook Comments


We’re glad to see you’re enjoying PACE-CME…
but how about a more personalized experience?

Register for free